Dr Rebecca Kristeleit specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She also has a special interest in novel therapies for gynaecological cancer and has led or been involved in a number of successful new drug applications such as rucaparib, lurbinectedin, and dostarlimab. Dr Kristeleit joined Guy's and St Thomas' NHS Foundation Trust in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy's Clinical Research Facility. She currently leads a number of Phase I-III clinical studies including the novel use of PARP inhibitors for gynaecological malignancies.
Dr Kristeleit first qualified in 1995 from the University of Manchester after initially completing a bachelor’s degree in medical science at the University of St Andrews. She then received an ERASMUS Scholarship which allowed her to study in Switzerland before finishing her elective at Massachusetts General Hospital, Harvard University. Following this, she went on to train in medical oncology at the Royal Marsden Hospital before embarking on a CRUK-funded clinical research fellowship during which she completed a PhD on the clinical pharmacology of HDAC inhibitors at the Institute of Cancer Research. She was also awarded a senior fellowship at the Royal Marsden Hospital's Drug Development Unit where she gained experience in early phase clinical trials. She was later appointed a clinical senior lecturer and subsequently an associate professor at UCL.
Dr Kristeleit is a member of the Target Ovarian Cancer Scientific Advisory Board, the Oncology and Haematology Expert Advisory Group for the Commission on Human Medicines, and has been elected to the ESMO Faculty from 2021 to 2025. She has a number of publications to her name and is often asked to speak at national and international conferences as well as advise pharmaceutical companies on their gynaecological cancer drug development.
Dr Kristeleit has previously served as Chair of the BGCS Scientific Committee, the UK Oncology Forum Gynaecology Track, and the ASCO Gynaecological Cancer Scientific Committee.